Literature DB >> 16182182

Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia.

Mohamed L Sorror, Wendy Leisenring, H Joachim Deeg, Paul J Martin, Rainer Storb.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16182182     DOI： 10.1016/j.bbmt.2005.05.016

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  12 in total

1.  The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.

Authors:  Teresa Caballero-Velázquez; Luis Ignacio Sánchez-Abarca; Silvia Gutierrez-Cosio; Belén Blanco; Cristina Calderon; Carmen Herrero; Soraya Carrancio; Concepción Serrano; Consuelo del Cañizo; Jesús F San Miguel; José A Pérez-Simón
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

Review 2.  Graft-versus-host disease and immunosuppression.

Authors:  Neena Kapoor
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 3.  Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.

Authors:  Ron Ram; Rainer Storb
Journal:  Leuk Lymphoma       Date:  2013-01-24

Review 4.  Mesenchymal stromal cells: a new tool against graft-versus-host disease?

Authors:  Frédéric Baron; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-29       Impact factor: 5.742

5.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Georg N Franke; Ginna G Laport; Thomas R Chauncey; Edward Agura; Richard T Maziarz; Amelia Langston; Parameswaran Hari; Michael A Pulsipher; Wolfgang Bethge; Firoozeh Sahebi; Benedetto Bruno; Michael B Maris; Andrew Yeager; Finn Bo Petersen; Lars Vindeløv; Peter A McSweeney; Kai Hübel; Marco Mielcarek; George E Georges; Dietger Niederwieser; Karl G Blume; David G Maloney; Rainer Storb
Journal:  JAMA       Date:  2011-11-02       Impact factor: 56.272

Review 6.  Updates in chronic graft-versus-host disease.

Authors:  Betty K Hamilton
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

7.  Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.

Authors:  Leo Luznik; Marcelo C Pasquini; Brent Logan; Robert J Soiffer; Juan Wu; Steven M Devine; Nancy Geller; Sergio Giralt; Helen E Heslop; Mary M Horowitz; Richard J Jones; Mark R Litzow; Adam Mendizabal; Lori Muffly; Eneida R Nemecek; Lynn O'Donnell; Richard J O'Reilly; Raquel Palencia; Johannes Schetelig; Leyla Shune; Scott R Solomon; Sumithira Vasu; Vincent T Ho; Miguel-Angel Perales
Journal:  J Clin Oncol       Date:  2021-12-02       Impact factor: 44.544

8.  The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.

Authors:  Jose Antonio Perez-Simón; Rodrigo Martino; Rocío Parody; Mónica Cabrero; Lucía Lopez-Corral; David Valcarcel; Carmen Martinez; Carlos Solano; Lourdes Vazquez; Francisco J Márquez-Malaver; Jordi Sierra; Dolores Caballero
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

9.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Mohamed L Sorror; Barry E Storer; Brenda M Sandmaier; Michael Maris; Judith Shizuru; Richard Maziarz; Edward Agura; Thomas R Chauncey; Michael A Pulsipher; Peter A McSweeney; James C Wade; Benedetto Bruno; Amelia Langston; Jerald Radich; Dietger Niederwieser; Karl G Blume; Rainer Storb; David G Maloney
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

Review 10.  Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?

Authors:  Rainer Storb; Joseph H Antin; Corey Cutler
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-24       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.